Leahy demands Myriad “march-in rights”

19-07-2013

Senator Patrick Leahy has urged the US National Institutes of Health (NIH) to force Myriad Genetics to license its patents directed to tests for breast and ovarian cancer.


senator patrick leahy, myriad genetics, brca1, brca2, dna, march-in rights, Bayh-Doyle Act

LSIPR